Oligodendrocytes and Alzheimer's disease

International Journal of Neuroscience

Volumn 126, Issue 2, 2016, Pages 97-104

  Cai, Zhiyou ^a   Xiao, Ming ^b  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimers disease; myelin; oligodendrocyte

Indexed keywords

AMYLOID BETA PROTEIN; MYELIN;

ALZHEIMER DISEASE; CELL REGENERATION; COGNITIVE DEFECT; DISEASE ASSOCIATION; HUMAN; NERVE CELL DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; OLIGODENDROGLIA; OSTEOPROGENITOR CELL; PROTEIN DEGRADATION; REVIEW; MYELIN SHEATH; PATHOLOGY;

ALZHEIMER DISEASE; HUMANS; MYELIN SHEATH; OLIGODENDROGLIA;

EID: 84949921035     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2015.1025778     Document Type: Review

References (109)

1. Daniilidou M, Koutroumani M, Tsolaki M. Epigenetic mechanisms in Alzheimer's disease. Curr Med Chem 2011; 18 (12): 1751-56.
2. Aqdam MJ, Kamali K, Rahgozar M, et al. Association of CALHM1 gene polymorphism with late onset Alzheimer's disease in Iranian population. Avicenna J Med Biotechnol 2010; 2 (3): 153-7.
3. Zhu Z, Li C, Wang X, et al. 2,2′,4′-trihydroxychalcone from Glycyrrhiza glabra as a new specific BACE1 inhibitor efficiently ameliorates memory impairment in mice. J Neurochem 2010; 114 (2): 374-85.
4. Strydom A, Chan T, King M, et al. Incidence of dementia in older adults with intellectual disabilities. Res Dev Disabil 2013; 34 (6): 1881-5.
5. de la Torre JC. Alzheimer's disease is incurable but preventable. J Alzheimers Dis 2010; 20 (3): 861-70.
6. Luth HJ, Apelt J, Ihunwo AO, et al. Degeneration of beta-amyloid-associated cholinergic structures in transgenic APP SW mice. Brain Res 2003; 977 (1): 16-22.
7. Belarbi K, Schindowski K, Burnouf S, et al. Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model. relevance to Alzheimer's disease. Curr Alzheimer Res 2009; 6 (2): 152-7.
8. Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer's disease-interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res 2005; 30 (6-7): 895-908.
9. Du H, Guo L, Yan SS. Synaptic mitochondrial pathology in Alzheimer's disease. Antioxid Redox Signal 2012; 16 (12): 1467-75.
10. Kopeikina KJ, Polydoro M, Tai HC, et al. Synaptic alterations in the rTg4510 mouse model of tauopathy. J Comp Neurol 2013; 521 (6): 1334-53.
11. Fuller S, Steele M, Munch G. Activated astroglia during chronic inflammation in Alzheimer's disease-do they neglect their neurosupportive roles? Mutat Res 2010; 690 (1-2): 40-9.
12. Drechsel DA, Estevez AG, Barbeito L, Beckman JS. Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS. Neurotox Res 2012; 22 (4): 251-64.
13. Rohn TT. The triggering receptor expressed on myeloid cells 2: "TREM-ming" the inflammatory component associated with Alzheimer's disease. Oxid Med Cell Longev 2013; 2013: 860959.
14. von Bernhardi R, Eugenin J. Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. Antioxid Redox Signal 2012; 16 (9): 974-1031.
15. Kamphuis W, Orre M, Kooijman L, et al. Differential cell proliferation in the cortex of the APPswePS1dE9 Alzheimer's disease mouse model. Glia 2012; 60 (4): 615-29.
16. Saitoh T, Kang D, Mallory M, et al. Glial cells in Alzheimer's disease: preferential effect of APOE risk on scattered microglia. Gerontology 1997; 43 (1-2): 109-18.
17. Bachstetter AD, Norris CM, Sompol P, et al. Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology. J Neurosci 2012; 32 (30): 10201-10.
18. Garwood CJ, Pooler AM, Atherton J, et al. Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis 2011; 2: e167.
19. von Bernhardi R, Ramirez G. Microglia-astrocyte interaction in Alzheimer's disease: friends or foes for the nervous system? Biol Res 2001; 34 (2): 123-8.
20. Meraz-Rios MA, Toral-Rios D, Franco-Bocanegra D, et al. Inflammatory process in Alzheimer's disease. Front Integr Neurosci 2013; 7: 59.
21. Potter GB, Rowitch DH, Petryniak MA. Myelin restoration: progress and prospects for human cell replacement therapies. Arch Immunol Ther Exp (Warsz) 2011; 59 (3): 179-93.
22. Franklin RJ, Kotter MR. The biology of CNS remyelination: the key to therapeutic advances. J Neurol 2008; 255 (Suppl. 1): 19-25.
23. Bradl M, Lassmann H. Oligodendrocytes: biology and pathology. Acta Neuropathol 2010; 119 (1): 37-53.
24. Thomson CE, McCulloch M, Sorenson A, et al. Myelinated, synapsing cultures of murine spinal cord-validation as an in vitro model of the central nervous system. Eur J Neurosci 2008; 28 (8): 1518-35.
25. Kotter MR, Stadelmann C, Hartung HP. Enhancing remyelination in disease-can we wrap it up? Brain 2011; 134 (Pt 7): 1882-1900.
26. Zawadzka M, Franklin RJ. Myelin regeneration in demyelinating disorders: new developments in biology and clinical pathology. Curr Opin Neurol 2007; 20 (3): 294-8.
27. Mitew S, Kirkcaldie MT, Halliday GM, et al. Focal demyelination in Alzheimer's disease and transgenic mouse models. Acta Neuropathol 2010; 119 (5): 567-77.
28. Bartzokis G. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging 2011; 32 (8): 1341-71.
29. Behrendt G, Baer K, Buffo A, et al. Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia 2013; 61 (2): 273-86.
30. Li JS, Yao ZX. Modulation of FGF receptor signaling as an intervention and potential therapy for myelin breakdown in Alzheimer's disease. Med Hypotheses 2013; 80 (4): 341-44.
31. Sjobeck M, Haglund M, Englund E. Decreasing myelin density reflected increasing white matter pathology in Alzheimer's disease-a neuropathological study. Int J Geriatr Psychiatry 2005; 20 (10): 919-26.
32. Funfschilling U, Supplie LM, Mahad D, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 2012; 485 (7399): 517-21.
33. Deng W, Poretz RD. Oligodendroglia in developmental neurotoxicity. Neurotoxicology 2003; 24 (2): 161-78.
34. Matthews PR, Eastwood SL, Harrison PJ. Reduced myelin basic protein and actin-related gene expression in visual cortex in schizophrenia. PLoS One 2012; 7 (6): e38211.
35. Hayashi Y, Nihonmatsu-Kikuchi N, Hisanaga S, et al. Neuropathological similarities and differences between schizophrenia and bipolar disorder: a flow cytometric postmortem brain study. PLoS One 2012; 7 (3): e33019.
36. Gutierrez-Fernandez A, Gonzalez-Pinto A, Vega P, et al. Expression of oligodendrocyte and myelin genes is not altered in peripheral blood cells of patients with first-episode schizophrenia and bipolar disorder. Bipolar Disord 2010; 12 (1): 107-9.
37. Konradi C, Sillivan SE, Clay HB. Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis. Neurobiol Dis 2012; 45 (1): 37-47.
38. Noetzel MJ, Brunstrom JE. The vulnerable oligodendrocyte: inflammatory observations on a cause of cerebral palsy. Neurology 2001; 56 (10): 1254-5.
39. Falahati S, Breu M, Waickman AT, et al. Ischemia-induced neuroinflammation is associated with disrupted development of oligodendrocyte progenitors in a model of periventricular leukomalacia. Dev Neurosci 2013; 35 (2-3): 182-96.
40. Sun J, Fang Y, Chen T, et al. WIN55, 212-2 promotes differentiation of oligodendrocyte precursor cells and improve remyelination through regulation of the phosphorylation level of the ERK 1/2 via cannabinoid receptor 1 after stroke-induced demyelination. Brain Res 2013; 1491: 225-35.
41. Sun J, Fang YQ, Ren H, et al. WIN55,212-2 protects oligodendrocyte precursor cells in stroke penumbra following permanent focal cerebral ischemia in rats. Acta Pharmacol Sin 2013; 34 (1): 119-28.
42. Arai K, Lo EH. Experimental models for analysis of oligodendrocyte pathophysiology in stroke. Exp Transl Stroke Med 2009; 1: 6.
43. Sortwell CE, Daley BF, Pitzer MR, et al. Oligodendrocyte-type 2 astrocyte-derived trophic factors increase survival of developing dopamine neurons through the inhibition of apoptotic cell death. J Comp Neurol 2000; 426 (1): 143-53.
44. Duyckaerts C, Verny M, Hauw JJ. Recent neuropathology of parkinsonian syndromes. Rev Neurol (Paris) 2003; 159 (5 Pt 2): 3S11-18.
45. Gagyi E, Kormos B, Castellanos KJ, et al. Decreased oligodendrocyte nuclear diameter in Alzheimer's disease and Lewy body dementia. Brain Pathol 2012; 22 (6): 803-10.
46. Desai MK, Mastrangelo MA, Ryan DA, et al. Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. Am J Pathol 2010; 177 (3): 1422-35.
47. Sims R, Hollingworth P, Moskvina V, et al. Evidence that variation in the oligodendrocyte lineage transcription factor 2 (OLIG2) gene is associated with psychosis in Alzheimer's disease. Neurosci Lett 2009; 461 (1): 54-9.
48. Desai MK, Guercio BJ, Narrow WC, Bowers WJ. An Alzheimer's disease-relevant presenilin-1 mutation augments amyloid-beta-induced oligodendrocyte dysfunction. Glia 2011; 59 (4): 627-40.
49. Lu PH, Lee GJ, Tishler TA, et al. Myelin breakdown mediates age-related slowing in cognitive processing speed in healthy elderly men. Brain Cogn 2013; 81 (1): 131-8.
50. Lu PH, Lee GJ, Raven EP, et al. Age-related slowing in cognitive processing speed is associated with myelin integrity in a very healthy elderly sample. J Clin Exp Neuropsychol 2011; 33 (10): 1059-68.
51. Bartzokis G, Lu PH, Mintz J. Quantifying age-related myelin breakdown with MRI: novel therapeutic targets for preventing cognitive decline and Alzheimer's disease. J Alzheimers Dis 2004; 6 (Suppl. 6): S53-59.
52. Bartzokis G, Lu PH, Tingus K, et al. Lifespan trajectory of myelin integrity and maximum motor speed. Neurobiol Aging 2010; 31 (9): 1554-62.
53. Desai MK, Sudol KL, Janelsins MC, et al. Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 2009; 57 (1): 54-65.
54. Radde R, Bolmont T, Kaeser SA, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006; 7 (9): 940-6.
55. Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39 (3): 409-21.
56. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Neuron 1995; 373 (6514): 523-7.
57. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 2004; 25 (1): 5-18; author reply 49-62.
58. Bartzokis G, Sultzer D, Lu PH, et al. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiol Aging 2004; 25 (7): 843-51.
59. Bartzokis G, Lu PH, Mintz J. Human brain myelination and amyloid beta deposition in Alzheimer's disease. Alzheimers Dement 2007; 3 (2): 122-5.
60. Bartzokis G, Lu PH, Tishler TA, et al. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res 2007; 32 (10): 1655-64.
61. Jantaratnotai N, Ryu JK, Kim SU, McLarnon JG. Amyloid beta peptide-induced corpus callosum damage and glial activation in vivo. Neuroreport 2003; 14 (11): 1429-33.
62. Roher AE, Weiss N, Kokjohn TA, et al. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 2002; 41 (37): 11080-90.
63. Agosta F, Dalla Libera D, Spinelli EG, et al. Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and Alzheimer disease. Ann Neurol 2014; 76 (6): 813-25.
64. Horiuchi M, Maezawa I, Itoh A, et al. Amyloid beta1-42 oligomer inhibits myelin sheet formation in vitro. Neurobiol Aging 2012; 33 (3): 499-509.
65. Singhrao SK, Neal JW, Piddlesden SJ, Newman GR. New immunocytochemical evidence for a neuronal/oligodendroglial origin for corpora amylacea. Neuropathol Appl Neurobiol 1994; 20 (1): 66-73.
66. Glezer I, Lapointe A, Rivest S. Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries. FASEB J 2006; 20 (6): 750-2.
67. Lang J, Maeda Y, Bannerman P, et al. Adenomatous polyposis coli regulates oligodendroglial development. J Neurosci 2013; 33 (7): 3113-30.
68. Xu J, Chen S, Ahmed SH, et al. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci 2001; 21 (1): RC118.
69. Alberghina L, Colangelo AM. The modular systems biology approach to investigate the control of apoptosis in Alzheimer's disease neurodegeneration. BMC Neurosci 2006; 7 (Suppl. 1): S2.
70. Behl C, Moosmann B. Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotective compounds. Biol Chem 2002; 383 (3-4): 521-36.
71. Lee JT, Xu J, Lee JM, et al. Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 2004; 164 (1): 123-31.
72. Aluise CD, Robinson RA, Beckett TL, et al. Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics. Neurobiol Dis 2010; 39 (2): 221-8.
73. Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med 2010; 4 (1): 27-36.
74. Galimberti D, Scarpini E. Inflammation and oxidative damage in Alzheimer's disease: friend or foe? Front Biosci (Schol Ed) 2011; 3: 252-66.
75. Cai Z, Zhao B, Ratka A. Oxidative stress and beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 2011; 13 (4): 223-50.
76. Akterin S, Cowburn RF, Miranda-Vizuete A, et al. Involvement of glutaredoxin-1 and thioredoxin-1 in beta-amyloid toxicity and Alzheimer's disease. Cell Death Differ 2006; 13 (9): 1454-65.
77. Camins A, Pallas M, Silvestre JS. Apoptotic mechanisms involved in neurodegenerative diseases: experimental and therapeutic approaches. Methods Find Exp Clin Pharmacol 2008; 30 (1): 43-65.
78. Quintana C, Bellefqih S, Laval JY, et al. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J Struct Biol 2006; 153 (1): 42-54.
79. Schonberg DL, Goldstein EZ, Sahinkaya FR, et al. Ferritin stimulates oligodendrocyte genesis in the adult spinal cord and can be transferred from macrophages to NG2 cells in vivo. J Neurosci 2012; 32 (16): 5374-84.
80. Wang C, Li J, Liu Q, et al. Hydrogen-rich saline reduces oxidative stress and inflammation by inhibit of JNK and NF-kappaB activation in a rat model of amyloid-beta-induced Alzheimer's disease. Neurosci Lett 2011; 491 (2): 127-32.
81. Cai Z, Hussain MD, Yan LJ. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease. Int J Neurosci 2014; 124 (5): 307-21.
82. Chen CH, Zhou W, Liu S, et al. Increased NF-kappaB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. Int J Neuropsychopharmacol 2012; 15 (1): 77-90.
83. Cai Z, Zhao Y, Zhao B. Roles of glycogen synthase kinase 3 in Alzheimer's disease. Curr Alzheimer Res 2012; 9 (7): 864-79.
84. Lin S, Liu H, Kanawati B, et al. Hippocampal metabolomics using ultrahigh-resolution mass spectrometry reveals neuroinflammation from Alzheimer's disease in CRND8 mice. Anal Bioanal Chem 2013; 405 (15): 5105-17.
85. Sirko S, Behrendt G, Johansson PA, et al. Reactive glia in the injured brain acquire stem cell properties in response to sonic hedgehog [corrected]. Cell Stem Cell 2013; 12 (4): 426-39.
86. Lourhmati A, Buniatian GH, Paul C, et al. Age-dependent astroglial vulnerability to hypoxia and glutamate: the role for erythropoietin. PLoS One 2013; 8 (10): e77182.
87. Thangavel R, Van Hoesen GW, Zaheer A. The abnormally phosphorylated tau lesion of early Alzheimer's disease. Neurochem Res 2009; 34 (1): 118-23.
88. Fukutani Y, Sasaki K, Mukai M, et al. Neurons and extracellular neurofibrillary tangles in the hippocampal subdivisions in early-onset familial Alzheimer's disease: a case study. Psychiatry Clin Neurosci 1997; 51 (4): 227-31.
89. Han SH, Hulette C, Saunders AM, et al. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Exp Neurol 1994; 128 (1): 13-26.
90. Ulrich J. Senile plaques and neurofibrillary tangles of the Alzheimer type in nondemented individuals at presenile age. Gerontology 1982; 28 (2): 86-90.
91. Motte J, Williams RS. Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain. Acta Neuropathol 1989; 77 (5): 535-46.
92. Zhang M, Wang X, Jiang F, et al. Mitotic epitopes are incorporated into age-dependent neurofibrillary tangles in Niemann-Pick disease type C. Brain Pathol 2010; 20 (2): 367-77.
93. Lovell MA, Robertson JD, Buchholz BA, et al. Use of bomb pulse carbon-14 to age senile plaques and neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging 2002; 23 (2): 179-86.
94. Dani SU, Pittella JE, Boehme A, et al. Progressive formation of neuritic plaques and neurofibrillary tangles is exponentially related to age and neuronal size. A morphometric study of three geographically distinct series of aging people. Dement Geriatr Cogn Disord 1997; 8 (4): 217-27.
95. Mesulam MM, Asuncion Moran M. Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease. Ann Neurol 1987; 22 (2): 223-8.
96. Ferrer I, Gomez-Isla T, Puig B, et al. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2005; 2 (1): 3-18.
97. Gotz J, Tolnay M, Barmettler R, et al. Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. Eur J Neurosci 2001; 13 (11): 2131-40.
98. Nishimura M, Tomimoto H, Suenaga T, et al. Immunocytochemical characterization of glial fibrillary tangles in Alzheimer's disease brain. Am J Pathol 1995; 146 (5): 1052-58.
99. Heckl S, Pipkorn R, Nagele T, et al. Molecular imaging: bridging the gap between neuroradiology and neurohistology. Histol Histopathol 2004; 19 (2): 651-68.
100. Cai Z, Yan LJ. Rapamycin, autophagy, and Alzheimer's disease. J Biochem Pharmacol Res 2013; 1 (2): 84-90.
101. Rozemuller AJ, Jansen C, Carrano A, et al. Neuroinflammation and common mechanism in Alzheimer's disease and prion amyloidosis: amyloid-associated proteins, neuroinflammation and neurofibrillary degeneration. Neurodegener Dis 2012; 10 (1-4): 301-4.
102. Huehnchen P, Prozorovski T, Klaissle P, et al. Modulation of adult hippocampal neurogenesis during myelin-directed autoimmune neuroinflammation. Glia 2011; 59 (1): 132-42.
103. Levine JM, Reynolds R, Fawcett JW. The oligodendrocyte precursor cell in health and disease. Trends Neurosci 2001; 24 (1): 39-47.
104. Svennerholm L, Gottfries CG. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem 1994; 62 (3): 1039-47.
105. Wallin A, Gottfries CG, Karlsson I, Svennerholm L. Decreased myelin lipids in Alzheimer's disease and vascular dementia. Acta Neurol Scand 1989; 80 (4): 319-23.
106. Yokoi S, Nakano T, Suzuki K. Studies in the white matter of Alzheimer's disease-morphological, lipid-chemical investigation. No To Shinkei 1982; 34 (12): 1197-205.
107. Soderberg M, Edlund C, Alafuzoff I, et al. Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type. J Neurochem 1992; 59 (5): 1646-53.
108. Tian J, Shi J, Bailey K, Mann DM. Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss from cerebral cortical white matter in Alzheimer's disease. Neuropathol Appl Neurobiol 2004; 30 (1): 46-56.
109. Ihara M, Polvikoski TM, Hall R, et al. Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. Acta Neuropathol 2010; 119 (5): 579-89.